P&K Skin Research Center Co. Ltd Asset Resilience Ratio
P&K Skin Research Center Co. Ltd asset resilience ratio. P&K Skin Research Center Co. Ltd (347740) has an Asset Resilience Ratio of 41.86% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See P&K Skin Research Center Co. Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of P&K Skin Research Center Co. Ltd (2018–2024)
Asset resilience ratio of P&K Skin Research Center Co. Ltd from 2018 to 2024. This chart shows how P&K Skin Research Center Co. Ltd's Asset Resilience Ratio has changed over time. Read 347740 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down P&K Skin Research Center Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 347740 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩35.95 Billion | 41.86% |
| Total Liquid Assets | ₩35.95 Billion | 41.86% |
Asset Resilience Insights
- Very High Liquidity: P&K Skin Research Center Co. Ltd maintains exceptional liquid asset reserves at 41.86% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
P&K Skin Research Center Co. Ltd Industry Peers by Asset Resilience Ratio
Compare P&K Skin Research Center Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Diagnósticos da América S.A
SA:DASA3 |
Diagnostics & Research | 10.42% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
P&K Skin Research Center Co. Ltd Asset Resilience Ratio by Year (2018–2024)
P&K Skin Research Center Co. Ltd asset resilience ratio by year from 2018 to 2024. The table below shows the annual Asset Resilience Ratio data for P&K Skin Research Center Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.62% | ₩40.71 Billion ≈ $27.59 Million |
₩82.04 Billion ≈ $55.60 Million |
-8.11pp |
| 2023-12-31 | 57.73% | ₩44.69 Billion ≈ $30.28 Million |
₩77.41 Billion ≈ $52.46 Million |
-19.36pp |
| 2022-12-31 | 77.09% | ₩57.46 Billion ≈ $38.94 Million |
₩74.54 Billion ≈ $50.51 Million |
+14.12pp |
| 2021-12-31 | 62.97% | ₩42.25 Billion ≈ $28.63 Million |
₩67.09 Billion ≈ $45.47 Million |
-20.05pp |
| 2020-12-31 | 83.02% | ₩49.72 Billion ≈ $33.70 Million |
₩59.89 Billion ≈ $40.59 Million |
+1.66pp |
| 2019-12-31 | 81.36% | ₩22.76 Billion ≈ $15.42 Million |
₩27.97 Billion ≈ $18.95 Million |
+16.89pp |
| 2018-12-31 | 64.47% | ₩11.37 Billion ≈ $7.71 Million |
₩17.64 Billion ≈ $11.95 Million |
-- |
About P&K Skin Research Center Co. Ltd
P&K Skin Research Center Co., Ltd. engages in the evaluation and research of dermatological products in South Korea. It provides scientific information and technical support services for new cosmetic raw material development, functional cosmetics, and human application testing of quasi-drugs. The company performs human application, safety, efficacy, cosmeceuticals, health food, sensory, and in vi… Read more